The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 29 of the 53 sources its claims cite were checked for support.
Psychobiotics in mental health: insights from human clinical trials via the gut-brain axis
Open accessAbstract
Recent research has highlighted the gut-brain axis as a critical modulator of mental health, positioning probiotics as promising psychobiotic interventions for anxiety, stress, depression, and cognitive function. Clinical trials investigating strains such as Lactobacillus rhamnosus, Bifidobacterium longum, Lactobacillus gasseri , and multi-strain formulations have demonstrated strain- and context-specific effects on psychological and physiological outcomes. While some studies reported improvements in mood, anxiety, sleep quality, and cognitive performance, others showed limited effects, particularly in healthy populations with low baseline stress levels, reflecting the challenges of translating preclinical findings into clinical applications in humans. Mechanistic evidence suggests that psychobiotics may influence neuroactive metabolites, short-chain fatty acids, γ -aminobutyric acid, serotonin, and anti-inflammatory pathways, thereby modulating cognitive and emotional processes. The effects happen dependent on factors such as dosage, strain specificity, delivery method, baseline stress or symptom levels, and co-administration with conventional treatments. Collectively, these findings underscore the potential of targeted psychobiotics to enhance mental well-being and support stress resilience, while highlighting the need for carefully designed clinical trials to clarify efficacy and mechanisms.
Overview
CoChat Summary
## TL;DR
This structured narrative review synthesizes human clinical trials of psychobiotics and finds that benefits are usually strain-specific, dose-dependent, and more evident in people with higher baseline stress or mood vulnerability. The paper concludes that psychobiotics can affect anxiety, stress, sleep, cognition, and related physiology through the gut-brain axis, but effects are inconsistent in healthy or low-stress populations.
## Key findings
- In an RPCT of 86 healthy college students over 28 days, a multi-strain psychobiotic improved panic and neurophysiological anxiety, negative affect, worry, and negative mood regulation; post hoc analyses suggested CFU level mattered more than species count.
- In an RDBPCOT of 29 healthy male participants, Lactobacillus rhamnosus JB-1 showed no significant effects on mood, anxiety, sleep quality, cognition, inflammatory markers, or HPA stress response versus placebo.
- In a study of 71 participants with mild to severe depression over 8 weeks, Ecologic® BARRIER produced a significantly greater reduction in cognitive reactivity, especially in those with mild to moderate depression; the paper notes high attrition.
- Across trials, reported effects included improvements in sleep quality and duration, cortisol, sIgA/IL-10, processing speed, hyperactivity, and depressive cognitive patterns, but the paper emphasizes that outcomes were strain-specific, domain-specific, and population-dependent.
## Methods
- The paper is a structured narrative review of human clinical trials on psychobiotics and mental health via the gut-brain axis.
- It searched Scopus, ScienceDirect, Nature, PubMed, Google Scholar, and ClinicalTrials.gov for studies from 2016 to 2025, using keywords including psychobiotics, probiotics, gut-brain axis, mental health, clinical trials, depression, anxiety, and human studies.
- Included studies were peer-reviewed English-language human clinical trials assessing mental health outcomes and gut-brain-axis mechanisms; animal, in vitro, review, editorial, commentary, and conference abstract papers were excluded.
## Limitations
- The paper states that, because this is a narrative review, database retrieval numbers were not prospectively recorded and no PRISMA flow diagram is provided.
- The paper itself notes that the reviewed trials often had small samples, short intervention durations, high attrition in some studies, and mixed or null findings in healthy/low-stress populations.
- Evident from the text: the review is not a meta-analysis and does not report pooled effect sizes; its conclusions therefore depend on the heterogeneous trial reports it summarizes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
21 Valid · 7 Not valid · 34 Not checked · 61 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although no significant effects of psychobiotic supplementation were observed across the full sample, healthy lifestyle behaviors were consistently associated with improved well-being outcomes.”
§ Psychobiotics in mental health: insights from human clinical trials via the gut-brain axis > Key findings of recent clinical trials > Effects on healthy subjects In an RDBPCOT involving 29 healthy male participants, the impact of Lactobacillus rhamnosus JB-1 on stress-related behaviors, physiological responses, inflammation, cognitive function, and brain activity was assessed. Despite promising preclinical findings in animal models, the study found no significant effects of JB-1 on mood, anxiety, sleep quality, or cognitive performance compared to placebo. Additionally, there were no notable changes in inflammatory markers or the HPA stress response. These results underscore the challenges of translating preclinical psychobiotic findings from animal models to human populations and highlight the need for further research in clinical populations, especially those with stress-related disorders (Kelly et al., 2017). The relatively short intervention duration may have limited the detection of longer-term psychobiotic effects. Psychobiotic efficacy depends not only on dose, duration, and microbial colonization but also on the ability of probiotic strains to produce neuroactive metabolites that influence central nervous system signaling. Certain Lactobacillus and Bifidobacterium species are capable of synthesizing GABA, serotonin precursors, and indole-derived metabolites that modulate neural, immune, and endocrine pathways of gut-brain communication. If the administered strain exhibits limited activity in these metabolic pathways, particularly those influencing GABAergic signaling or tryptophan metabolism, clinical effects on anxiety may be minimal. The healthy adults were supplemented with Lactobacillus helveticus R0052 and Bifidobacterium longum R0175. Psychological outcomes, including well-being, quality of life, anxiety, emotional regulation, mindfulness, and interoceptive awareness, were assessed. Although no significant effects of psychobiotic supplementation were observed across the full sample, healthy lifestyle behaviors were consistently associated with improved well-being outcomes. Notably, interaction analyses revealed that psychobiotic intake produced beneficial post-treatment effects on anxiety, emotional regulation, and mindfulness only among participants with higher adherence to healthy behaviors. These findings suggest that psychobiotic efficacy may depend on broader lifestyle context rather than probiotic intake alone. Overall, the study underscores the importance of accounting for lifestyle variables in psychobiotic and mental health research and supports an embodied, bottom-up framework for understanding psychological functioning (Morales-Torres et al., 2023). Bifidobacterium breve M-16 V has been investigated as a psychobiotic with potential effects on mood, sleep, and autonomic nervous system regulation. The supplementation of M-16 V was well tolerated and compliant; participants with higher baseline anxiety demonstrated improvements in mood and sleep scores. Supplementation also decreased stress-related heart rate responses and increased fecal pipecolic acid levels, suggesting modulation of the gut-brain axis. These findings indicate that M-16 V may influence autonomic nervous system balance and gut-derived neuromodulators, potentially contributing to enhanced mood and sleep in individuals experiencing elevated anxiety. The study supports further exploration of this psychobiotic for stress-related outcomes, particularly in populations with higher baseline anxiety or mood vulnerability (Mutoh et al., 2024). The effects of micro-encapsulated and non-encapsulated Lacticaseibacillus rhamnosus HN001 in community-dwelling individuals on brain health and cognitive function were recently reported. Resting-state functional magnetic resonance imaging revealed significant differences in functional connectivity within regions associated with visual processing and perception between the two probiotic formulations, although no changes in brain morphometry were observed. Secondary outcomes included magnetic resonance spectroscopy, quantification of GABA and glutamate, as well as peripheral markers, such as serotonin and brain-derived neurotrophic factor (BDNF). While peripheral serotonin levels showed significant changes over time, no notable differences were detected in GABA, glutamate, or BDNF. Cognitive testing indicated significant improvements in processing speed, whereas other domains, including short-term memory, anxiety, depression, perceived stress, and sleep quality, remained largely unaffected. The study design, which ranked participants by sex and age and employed high compliance and quality control in neuroimaging data acquisition, provided robust insight into psychobiotic effects on brain function. Micro-encapsulation appeared to influence gut delivery and, consequently, the impact on functional brain connectivity. Limitations included potential learning effects on repeated cognitive tests despite the use of alternative test versions, as well as the possibility of random fluctuations influencing specific test outcomes. Nonetheless, the study demonstrates that targeted psychobiotic interventions can modulate functional connectivity in the aging brain and selectively improve cognitive performance. These findings underscore the importance of considering psychobiotic formulation and delivery methods in designing interventions for older adults, offering promising avenues for supporting cognitive health through gut-brain axis modulation in healthy aging populations (Rode et al., 2025). Rather than producing broad psychological improvements, psychobiotics may influence selective neurobiological or cognitive domains. JB-1 showed no effect on mood or HPA activity, yet HN001 modulated functional brain connectivity and processing speed without affecting emotional outcomes. Similarly, M-16 V altered autonomic responses and gut-derived metabolites. This suggests that psychobiotics may first alter neural circuitry or physiological regulation before producing detectable subjective mood changes.
What the sources say
- Supportedcites Morales-Torres et al., 2023 source
The Probiotic Treatment section identifies the supplemented strains, and the Discussion reports no significant effect of probiotics on psychological outcomes in the overall healthy-adult sample. The Discussion also reports that healthy behaviors correlated with well-being measures, consistent with the citing sentence. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clinical studies indicate that combinations of Lactobacillus and Bifidobacterium strains can exert beneficial effects on stress, anxiety, and broader psychopathological outcomes in healthy populations, as assessed using validated psychological scales (de Le Morvan Sequeira et al., 2022; Messaoudi et al., 2011).”
§ Psychobiotics in mental health: insights from human clinical trials via the gut-brain axis > Introduction
What the sources say
- Partly supportedcites de Le Morvan Sequeira et al., 2022 sourceExperimental — accuracy not yet measured
The Results (§§3.2–3.3; page unavailable) describe studies of healthy participants using validated questionnaires and find a slight probiotic-favoring effect on stress. The review also lists a Lactobacillus–Bifidobacterium formulation, but it does not establish that such combinations benefit all three claimed outcomes in healthy people: most studies found no group difference for anxiety or psychiatric distress, and the Discussion (§4; page unavailable) questions the clinical relevance of the small effects. (LLM, conf=0.86)
- Partly supportedcites Messaoudi et al., 2011 sourceExperimental — accuracy not yet measured
The Abstract (p. 1) and Clinical study results (p. 5) report improved psychological-distress scores in healthy volunteers given the L. helveticus–B. longum combination, using the HSCL-90 and HADS. But the HADS anxiety comparison was a trend (P = 0.06), and the Perceived Stress Scale showed no treatment-group difference. Thus, the claim overstates the evidence for benefits on anxiety and stress as measured by psychological scales. (LLM, conf=0.86)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Psychobiotics may attenuate anxiety through coordinated modulation of the Amygdala and the hypothalamic–pituitary–adrenal (HPA) axis, two central systems governing emotional reactivity and stress physiology (Cryan et al., 2019).”
§ Psychobiotics in mental health: insights from human clinical trials via the gut-brain axis > Introduction
What the sources say
- Partly supportedcites Cryan et al., 2019 sourceExperimental — accuracy not yet measured
The “Probiotics and Psychobiotics” section reports anxiolytic effects and reduced corticosterone with a candidate psychobiotic; the “Fear” section describes the amygdala’s role in fear regulation. The paper does not establish that psychobiotics attenuate anxiety through coordinated modulation of the amygdala and HPA axis. In “Human studies,” a probiotic altered amygdala responses but did not reduce anxiety. (LLM, conf=0.84)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Notably, interaction analyses revealed that psychobiotic intake produced beneficial post-treatment effects on anxiety, emotional regulation, and mindfulness only among participants with higher adherence to healthy behaviors.”
§ Psychobiotics in mental health: insights from human clinical trials via the gut-brain axis > Key findings of recent clinical trials > Effects on healthy subjects In an RDBPCOT involving 29 healthy male participants, the impact of Lactobacillus rhamnosus JB-1 on stress-related behaviors, physiological responses, inflammation, cognitive function, and brain activity was assessed. Despite promising preclinical findings in animal models, the study found no significant effects of JB-1 on mood, anxiety, sleep quality, or cognitive performance compared to placebo. Additionally, there were no notable changes in inflammatory markers or the HPA stress response. These results underscore the challenges of translating preclinical psychobiotic findings from animal models to human populations and highlight the need for further research in clinical populations, especially those with stress-related disorders (Kelly et al., 2017). The relatively short intervention duration may have limited the detection of longer-term psychobiotic effects. Psychobiotic efficacy depends not only on dose, duration, and microbial colonization but also on the ability of probiotic strains to produce neuroactive metabolites that influence central nervous system signaling. Certain Lactobacillus and Bifidobacterium species are capable of synthesizing GABA, serotonin precursors, and indole-derived metabolites that modulate neural, immune, and endocrine pathways of gut-brain communication. If the administered strain exhibits limited activity in these metabolic pathways, particularly those influencing GABAergic signaling or tryptophan metabolism, clinical effects on anxiety may be minimal. The healthy adults were supplemented with Lactobacillus helveticus R0052 and Bifidobacterium longum R0175. Psychological outcomes, including well-being, quality of life, anxiety, emotional regulation, mindfulness, and interoceptive awareness, were assessed. Although no significant effects of psychobiotic supplementation were observed across the full sample, healthy lifestyle behaviors were consistently associated with improved well-being outcomes. Notably, interaction analyses revealed that psychobiotic intake produced beneficial post-treatment effects on anxiety, emotional regulation, and mindfulness only among participants with higher adherence to healthy behaviors. These findings suggest that psychobiotic efficacy may depend on broader lifestyle context rather than probiotic intake alone. Overall, the study underscores the importance of accounting for lifestyle variables in psychobiotic and mental health research and supports an embodied, bottom-up framework for understanding psychological functioning (Morales-Torres et al., 2023). Bifidobacterium breve M-16 V has been investigated as a psychobiotic with potential effects on mood, sleep, and autonomic nervous system regulation. The supplementation of M-16 V was well tolerated and compliant; participants with higher baseline anxiety demonstrated improvements in mood and sleep scores. Supplementation also decreased stress-related heart rate responses and increased fecal pipecolic acid levels, suggesting modulation of the gut-brain axis. These findings indicate that M-16 V may influence autonomic nervous system balance and gut-derived neuromodulators, potentially contributing to enhanced mood and sleep in individuals experiencing elevated anxiety. The study supports further exploration of this psychobiotic for stress-related outcomes, particularly in populations with higher baseline anxiety or mood vulnerability (Mutoh et al., 2024). The effects of micro-encapsulated and non-encapsulated Lacticaseibacillus rhamnosus HN001 in community-dwelling individuals on brain health and cognitive function were recently reported. Resting-state functional magnetic resonance imaging revealed significant differences in functional connectivity within regions associated with visual processing and perception between the two probiotic formulations, although no changes in brain morphometry were observed. Secondary outcomes included magnetic resonance spectroscopy, quantification of GABA and glutamate, as well as peripheral markers, such as serotonin and brain-derived neurotrophic factor (BDNF). While peripheral serotonin levels showed significant changes over time, no notable differences were detected in GABA, glutamate, or BDNF. Cognitive testing indicated significant improvements in processing speed, whereas other domains, including short-term memory, anxiety, depression, perceived stress, and sleep quality, remained largely unaffected. The study design, which ranked participants by sex and age and employed high compliance and quality control in neuroimaging data acquisition, provided robust insight into psychobiotic effects on brain function. Micro-encapsulation appeared to influence gut delivery and, consequently, the impact on functional brain connectivity. Limitations included potential learning effects on repeated cognitive tests despite the use of alternative test versions, as well as the possibility of random fluctuations influencing specific test outcomes. Nonetheless, the study demonstrates that targeted psychobiotic interventions can modulate functional connectivity in the aging brain and selectively improve cognitive performance. These findings underscore the importance of considering psychobiotic formulation and delivery methods in designing interventions for older adults, offering promising avenues for supporting cognitive health through gut-brain axis modulation in healthy aging populations (Rode et al., 2025). Rather than producing broad psychological improvements, psychobiotics may influence selective neurobiological or cognitive domains. JB-1 showed no effect on mood or HPA activity, yet HN001 modulated functional brain connectivity and processing speed without affecting emotional outcomes. Similarly, M-16 V altered autonomic responses and gut-derived metabolites. This suggests that psychobiotics may first alter neural circuitry or physiological regulation before producing detectable subjective mood changes.
What the sources say
- Supportedcites Morales-Torres et al., 2023 source
Results §3.4 reports that participants with higher healthy-behavior scores had better post-treatment outcomes after probiotic intake for anxiety, difficulties in emotional regulation, and mindfulness. The Discussion likewise identifies the interaction between healthy behaviors and probiotic intake as the significant predictor of these outcomes, while noting no significant effect in the whole sample. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although no significant effects of psychobiotic supplementation were observed across the full sample, healthy lifestyle behaviors were consistently associated with improved well-being outcomes.”
§ Psychobiotics in mental health: insights from human clinical trials via the gut-brain axis > Key findings of recent clinical trials > Effects on healthy subjects In an RDBPCOT involving 29 healthy male participants, the impact of Lactobacillus rhamnosus JB-1 on stress-related behaviors, physiological responses, inflammation, cognitive function, and brain activity was assessed. Despite promising preclinical findings in animal models, the study found no significant effects of JB-1 on mood, anxiety, sleep quality, or cognitive performance compared to placebo. Additionally, there were no notable changes in inflammatory markers or the HPA stress response. These results underscore the challenges of translating preclinical psychobiotic findings from animal models to human populations and highlight the need for further research in clinical populations, especially those with stress-related disorders (Kelly et al., 2017). The relatively short intervention duration may have limited the detection of longer-term psychobiotic effects. Psychobiotic efficacy depends not only on dose, duration, and microbial colonization but also on the ability of probiotic strains to produce neuroactive metabolites that influence central nervous system signaling. Certain Lactobacillus and Bifidobacterium species are capable of synthesizing GABA, serotonin precursors, and indole-derived metabolites that modulate neural, immune, and endocrine pathways of gut-brain communication. If the administered strain exhibits limited activity in these metabolic pathways, particularly those influencing GABAergic signaling or tryptophan metabolism, clinical effects on anxiety may be minimal. The healthy adults were supplemented with Lactobacillus helveticus R0052 and Bifidobacterium longum R0175. Psychological outcomes, including well-being, quality of life, anxiety, emotional regulation, mindfulness, and interoceptive awareness, were assessed. Although no significant effects of psychobiotic supplementation were observed across the full sample, healthy lifestyle behaviors were consistently associated with improved well-being outcomes. Notably, interaction analyses revealed that psychobiotic intake produced beneficial post-treatment effects on anxiety, emotional regulation, and mindfulness only among participants with higher adherence to healthy behaviors. These findings suggest that psychobiotic efficacy may depend on broader lifestyle context rather than probiotic intake alone. Overall, the study underscores the importance of accounting for lifestyle variables in psychobiotic and mental health research and supports an embodied, bottom-up framework for understanding psychological functioning (Morales-Torres et al., 2023). Bifidobacterium breve M-16 V has been investigated as a psychobiotic with potential effects on mood, sleep, and autonomic nervous system regulation. The supplementation of M-16 V was well tolerated and compliant; participants with higher baseline anxiety demonstrated improvements in mood and sleep scores. Supplementation also decreased stress-related heart rate responses and increased fecal pipecolic acid levels, suggesting modulation of the gut-brain axis. These findings indicate that M-16 V may influence autonomic nervous system balance and gut-derived neuromodulators, potentially contributing to enhanced mood and sleep in individuals experiencing elevated anxiety. The study supports further exploration of this psychobiotic for stress-related outcomes, particularly in populations with higher baseline anxiety or mood vulnerability (Mutoh et al., 2024). The effects of micro-encapsulated and non-encapsulated Lacticaseibacillus rhamnosus HN001 in community-dwelling individuals on brain health and cognitive function were recently reported. Resting-state functional magnetic resonance imaging revealed significant differences in functional connectivity within regions associated with visual processing and perception between the two probiotic formulations, although no changes in brain morphometry were observed. Secondary outcomes included magnetic resonance spectroscopy, quantification of GABA and glutamate, as well as peripheral markers, such as serotonin and brain-derived neurotrophic factor (BDNF). While peripheral serotonin levels showed significant changes over time, no notable differences were detected in GABA, glutamate, or BDNF. Cognitive testing indicated significant improvements in processing speed, whereas other domains, including short-term memory, anxiety, depression, perceived stress, and sleep quality, remained largely unaffected. The study design, which ranked participants by sex and age and employed high compliance and quality control in neuroimaging data acquisition, provided robust insight into psychobiotic effects on brain function. Micro-encapsulation appeared to influence gut delivery and, consequently, the impact on functional brain connectivity. Limitations included potential learning effects on repeated cognitive tests despite the use of alternative test versions, as well as the possibility of random fluctuations influencing specific test outcomes. Nonetheless, the study demonstrates that targeted psychobiotic interventions can modulate functional connectivity in the aging brain and selectively improve cognitive performance. These findings underscore the importance of considering psychobiotic formulation and delivery methods in designing interventions for older adults, offering promising avenues for supporting cognitive health through gut-brain axis modulation in healthy aging populations (Rode et al., 2025). Rather than producing broad psychological improvements, psychobiotics may influence selective neurobiological or cognitive domains. JB-1 showed no effect on mood or HPA activity, yet HN001 modulated functional brain connectivity and processing speed without affecting emotional outcomes. Similarly, M-16 V altered autonomic responses and gut-derived metabolites. This suggests that psychobiotics may first alter neural circuitry or physiological regulation before producing detectable subjective mood changes.
What the sources say
- Supportedcites Morales-Torres et al., 2023 source
The Results (section 3.3) report significant correlations between healthy behaviors and multiple measures of well-being and mental health. The Discussion likewise states that higher healthy-behavior scores were associated with higher well-being and lower anxiety, supporting the citing sentence’s association claim. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
42 more claims · 4 with their cited sources checked
Create a free account to see all 123 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 71
- The quote only partly states this claim. 3
Citations
Cites
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286 · cited 2×
“Psychobiotics may attenuate anxiety through coordinated modulation of the Amygdala and the hypothalamic–pituitary–adrenal (HPA) axis, two central systems governing emotional reactivity and stress physiology (Cryan et al., 2019).”
Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
O’Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., & Cryan, J. F. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.027 · Cited by 2,012
Messaoudi, M., Lalonde, R., Violle, N., Javelot, H., Desor, D., Nejdi, A., Bisson, J.-F., Rougeot, C., Pichelin, M., Cazaubiel, M., et al. (2011) · British Journal of Nutrition · doi:10.1017/s0007114510004319 · Cited by 1,324
Psychobiotics: A novel class of psychotropic
Dinan, T. G., Stanton, C., & Cryan, J. F. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.05.001 · Cited by 1,287
γ-Aminobutyric acid production by culturable bacteria from the human intestine
Barrett, E., Ross, R. P., O'Toole, P. W., Fitzgerald, G. F., & Stanton, C. (2012) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2012.05344.x · Cited by 1,156 · cited 1×
“Notably, several psychobiotic strains within the Lactobacillus and Bifidobacterium genera, including Bifidobacterium dentium, Lactobacillus plantarum, and Lactobacillus brevis, can produce these neuroactive compounds (Schousboe and Waagepetersen, 2007; Barrett et al., 2012; O'Mahony et al., 2015).”
Chen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917
The Human Gut Microbiome: From Association to Modulation
Schmidt, T. S. B., Raes, J., & Bork, P. (2018) · Cell · doi:10.1016/j.cell.2018.02.044 · Cited by 845 · cited 1×
“Consequently, it has been proposed that microbiome-targeted interventions may impact psychological health in a manner that is strongly shaped by individual lifestyle patterns (Schmidt et al., 2018; Morales-Torres et al., 2023).”
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
The global burden of anxiety disorders in 2010
Baxter, A. J., Vos, T., Scott, K. M., Ferrari, A. J., & Whiteford, H. A. (2014) · Psychological Medicine · doi:10.1017/s0033291713003243 · Cited by 768
Short chain fatty acids: Microbial metabolites for gut-brain axis signalling
O'Riordan, K. J., Collins, M. K., Moloney, G. M., Knox, E. G., Aburto, M. R., Fülling, C., Morley, S. J., Clarke, G., Schellekens, H., & Cryan, J. F. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111572 · Cited by 713
Cited by
Gut–Brain–Skin Axis: From Mechanistic Insights to Translational Applications in Neurocosmetics
Zhao, R., Xu, H., Zhu, Y., Chang, H., Liu, B., & Liu, Z. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01892-x
Kyei-Baffour, V. O., Štreimikytė, P., Lastauskienė, E., Burokas, A., & Daliri, E. B. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109918
Александрович, Ч. А., Sokolyanskaya, L. O., Lukina, A. P., & Karnachuk, O. V. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1964473
Metadata
- Authors
- Sisubalan, N., Kesika, P., Sivamaruthi, B. S., & Chaiyasut, C.
- Affiliations
- University of Madras (IN)
- Chiang Mai University (TH)
- Corresponding author
- Sivamaruthi, Bhagavathi Sundaram
- Chaiyasut, Chaiyavat
- Venue
- Frontiers in microbiology
- Publisher
- Frontiers Media SA
- Published
- 2026-03-27
- Volume
- 17
- Pages
- 1804560-1804560
- ISSN
- 1664-302X (ISSN-L)
- PMC
- PMC13066224
- OpenAlex
- W7141684657
- Semantic Scholar
- d47a2711df36515a5644b6a1e4ca818d55042ab1
- Cited by
- 4
- References
- 54
- Citations by year
- 2026: 4
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Chiang Mai University
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- psychobiotics, gut-brain axis, probiotics, mental health, anxiety, depression, stress, cognitive function, Lactobacillus rhamnosus, Bifidobacterium longum, Lactobacillus gasseri, short-chain fatty acids, GABA, serotonin, neuroactive metabolites, anti-inflammatory pathways, sleep quality, strain specificity, stress resilience
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychobiotics in mental health: insights from human clinical trials via the gut-brain axis. https://app.cochat.ai/papers/10.3389/fmicb.2026.1804560
- The paper
- Sisubalan, N., Kesika, P., Sivamaruthi, B. S., & Chaiyasut, C. (2026). Psychobiotics in mental health: insights from human clinical trials via the gut-brain axis. Frontiers in microbiology. https://doi.org/10.3389/fmicb.2026.1804560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.